upadacitinib extended-release tablets,
for oral use Initial U.S. Approval: 2019

Rinvoq is a medicine that acts on the immune system (the body’s natural defences) and is used to treat: adults with moderate to severe rheumatoid arthritis (a disease that causes inflammation of the joints), adults with active psoriatic arthritis (inflammation of the joints associated with psoriasis, a disease causing red, scaly patches on the skin), adults with active axial spondyloarthritis (inflammation of the spine causing back pain), adults and children from 12 years of age with moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry), adults with ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) .

Facts about upadacitinib tablets

Approval Date: 2019
Proprietary Name: RINVOQ (upadacitinib) extended-release tablets
Active Ingredient(s): upadacitinib
FDA-approved use: rheumatoid arthritis
Dosage Form: Extended-release tablets: 15 mg
Medicine Approved By: US FDA
Manufacturer: AbbVie Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “upadacitinib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

read more